journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/29052164/the-role-of-condition-specific-preference-based-measures-in-health-technology-assessment
#1
REVIEW
Donna Rowen, John Brazier, Roberta Ara, Ismail Azzabi Zouraq
A condition-specific preference-based measure (CSPBM) is a measure of health-related quality of life (HRQOL) that is specific to a certain condition or disease and that can be used to obtain the quality adjustment weight of the quality-adjusted life-year (QALY) for use in economic models. This article provides an overview of the role and the development of CSPBMs, and presents a description of existing CSPBMs in the literature. The article also provides an overview of the psychometric properties of CSPBMs in comparison with generic preference-based measures (generic PBMs), and considers the advantages and disadvantages of CSPBMs in comparison with generic PBMs...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052163/the-use-of-health-state-utility-values-in-decision-models
#2
REVIEW
Roberta Ara, John Brazier, Ismail Azzabi Zouraq
Methodological issues of how to use health state utility values (HSUVs) in decision models arise frequently, including the most appropriate evidence to use as the baseline (e.g. the baseline HSUVs associated with avoiding a particular health condition or event), how to capture changes due to adverse events and how to appropriately capture uncertainty in progressive conditions where the expected change in quality of life is likely to be monotonically decreasing over time. As preference-based measures provide different values when collected from the same patient, it is important to ensure that all HSUVs used within a single model are obtained from the same instrument where ever possible...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052162/international-regulations-and-recommendations-for-utility-data-for-health-technology-assessment
#3
REVIEW
Donna Rowen, Ismail Azzabi Zouraq, Helene Chevrou-Severac, Ben van Hout
Recommendations and guidelines for the collection, generation, source and usage of utility data for health technology assessment (HTA) vary across different countries, with no international consensus. Many international agencies generate their own guidelines providing details on their preferred methods for HTA submissions, and there is variability in both what they recommend and the clarity and amount of detail provided in their guidelines. This article provides an overview of international regulations and recommendations for utility data in HTA for a selection of key HTA countries: Australia, Canada, France, Germany, the Netherlands, Spain (Catalonia), Sweden and the UK (England/Wales and Scotland)...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052161/sourcing-and-using-appropriate-health-state-utility-values-in-economic-models-in-health-care
#4
EDITORIAL
Roberta Ara, Tessa Peasgood, Clara Mukuria, Helene Chevrou-Severac, Donna Rowen, Ismail Azzabi-Zouraq, Suzy Paisley, Tracey Young, Ben van Hout, John Brazier
No abstract text is available yet for this article.
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052160/the-use-of-mapping-to-estimate-health-state-utility-values
#5
REVIEW
Roberta Ara, Donna Rowen, Clara Mukuria
Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision analytic model, for example to control for important sociodemographic variables (such as age or gender). This article provides an overview of the latest recommendations including pre-mapping considerations, the mapping process including data requirements for undertaking the estimation of mapping functions, regression models for estimating mapping functions, assessing performance and reporting standards for mapping studies...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052159/recommended-methods-for-the-collection-of-health-state-utility-value-evidence-in-clinical-studies
#6
REVIEW
Roberta Ara, John Brazier, Tracey Young
A conceptual model framework and an initial literature review are invaluable when considering what health state utility values (HSUVs) are required to populate health states in decision models. They are the recommended starting point early within a research and development programme, and before development of phase III trial protocols. While clinical trials can provide an opportunity to collect the required evidence, their appropriateness should be reviewed against the requirements of the model structure taking into account population characteristics, time horizon and frequency of clinical events...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052158/estimating-health-state-utility-values-for-comorbidities
#7
REVIEW
Roberta Ara, John Brazier
A comorbidity is defined as the presence of at least one additional health condition co-occurring with a primary health condition. Decision analytic models in healthcare depict the typical clinical pathway of patients in general clinical practice and frequently include health states defined to represent comorbidities such as sequelae or adverse events. Health state utility values (HSUVs) are often not available for these and analysts generally estimate them. This article provides a summary of the methodological literature on estimating methods frequently used together with worked examples...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052157/a-review-of-generic-preference-based-measures-for-use-in-cost-effectiveness-models
#8
REVIEW
John Brazier, Roberta Ara, Donna Rowen, Helene Chevrou-Severac
Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment weight required to calculate the quality-adjusted life year in health economic models. GPBMs have been developed to use across different interventions and medical conditions and typically consist of a self-complete patient questionnaire, a health state classification system, and preference weights for all states defined by the classification system. Of the six main GPBMs, the three most frequently used are the Health Utilities Index version 3, the EuroQol 5 dimensions (3 and 5 levels), and the Short Form 6 dimensions...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052156/the-identification-review-and-synthesis-of-health-state-utility-values-from-the-literature
#9
REVIEW
Roberta Ara, John Brazier, Tessa Peasgood, Suzy Paisley
Systematic literature reviews of health-related quality of life (HRQoL) evidence that are to inform economic models can be challenging due to the volume of hits identified in searches using generic terms for HRQoL. Nevertheless, a robust review of the literature is required to ensure that the health state utility values (HSUVs) used in the economic model are the most appropriate available. This article provides a synopsis of literature relating to identifying, reviewing and synthesising HSUVs. The process begins with scoping the needs of the economic model, including the definitions of health states and the requirements of any reimbursement agencies...
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052155/special-edition-on-utility-measurement-pharmacoeconomics
#10
EDITORIAL
Andrew Lloyd
No abstract text is available yet for this article.
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29052154/heath-state-utility-values-for-cost-effectiveness-models
#11
EDITORIAL
Jonathan Karnon
No abstract text is available yet for this article.
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29043567/impact-of-adverse-events-on-health-utility-and-health-related-quality-of-life-in-patients-receiving-first-line-chemotherapy-for-metastatic-breast-cancer-results-from-the-select-bc-study
#12
Yasuhiro Hagiwara, Takeru Shiroiwa, Kojiro Shimozuma, Takuya Kawahara, Yukari Uemura, Takanori Watanabe, Naruto Taira, Takashi Fukuda, Yasuo Ohashi, Hirofumi Mukai
OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation...
October 17, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29032493/disease-modifying-therapies-for-multiple-sclerosis-a-systematic-literature-review-of-cost-effectiveness-studies
#13
REVIEW
Sergio Iannazzo, Ange-Christelle Iliza, Louise Perrault
INTRODUCTION AND OBJECTIVE: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. MS is considered incurable; however, disease treatment has advanced significantly over the past several decades with the introduction of disease-modifying therapies (DMTs). The current study reviewed the cost-effectiveness analyses of DMTs in relapsing-remitting MS (RRMS) patients. METHODS: A systematic literature search of bibliographic databases was conducted to identify economic evaluations published after 2007...
October 14, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28975582/using-latent-class-analysis-to-model-preference-heterogeneity-in-health-a-systematic-review
#14
REVIEW
Mo Zhou, Winter Maxwell Thayer, John F P Bridges
BACKGROUND: Latent class analysis (LCA) has been increasingly used to explore preference heterogeneity, but the literature has not been systematically explored and hence best practices are not understood. OBJECTIVE: We sought to document all applications of LCA in the stated-preference literature in health and to inform future studies by identifying current norms in published applications. METHODS: We conducted a systematic review of the MEDLINE, EMBASE, EconLit, Web of Science, and PsycINFO databases...
October 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28975551/value-based-pricing-do-not-throw-away-the-baby-with-the-bath-water
#15
LETTER
Mattias Neyt
No abstract text is available yet for this article.
October 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28956321/comment-on-replicating-health-economic-models-firm-foundations-or-a-house-of-cards
#16
LETTER
Emma McManus, Tracey Sach
No abstract text is available yet for this article.
September 27, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28956295/response-to-comment-on-replicating-health-economic-models-firm-foundations-or-a-house-of-cards
#17
LETTER
Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
No abstract text is available yet for this article.
September 27, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28933003/research-costs-investigated-a-study-into-the-budgets-of-dutch-publicly-funded-drug-related-research
#18
Thea van Asselt, Bram Ramaekers, Isaac Corro Ramos, Manuela Joore, Maiwenn Al, Ivonne Lesman-Leegte, Maarten Postma, Pepijn Vemer, Talitha Feenstra
BACKGROUND: The costs of performing research are an important input in value of information (VOI) analyses but are difficult to assess. OBJECTIVE: The aim of this study was to investigate the costs of research, serving two purposes: (1) estimating research costs for use in VOI analyses; and (2) developing a costing tool to support reviewers of grant proposals in assessing whether the proposed budget is realistic. METHODS: For granted study proposals from the Netherlands Organization for Health Research and Development (ZonMw), type of study, potential cost drivers, proposed budget, and general characteristics were extracted...
September 20, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28933002/mepolizumab-for-treating-severe-eosinophilic-asthma-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#19
REVIEW
Iñigo Bermejo, Matt Stevenson, Katy Cooper, Sue Harnan, Jean Hamilton, Mark Clowes, Christopher Carroll, Tim Harrison, Shironjit Saha
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab (Nucala(®)) to submit evidence on the clinical and cost effectiveness of mepolizumab for the treatment of severe eosinophilic asthma. The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at the University of Sheffield was commissioned to act as the independent evidence review group (ERG). The ERG produced a review of the evidence for the clinical and cost effectiveness of mepolizumab as add-on to standard of care (SoC) compared with SoC and omalizumab, based upon the company's submission to NICE...
September 20, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28914440/olaratumab-in-combination-with-doxorubicin-for-the-treatment-of-advanced-soft-tissue-sarcoma-an-evidence-review-group-perspective-of-a-national-institute-for-health-and-care-excellence-single-technology-appraisal
#20
REVIEW
Irina A Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C Warren, Sophie Robinson, Peter Stephens, Martin Hoyle
The manufacturer of olaratumab (Lartruvo(®)), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process. The Peninsula Technology Assessment Group, commissioned to act as the Evidence Review Group (ERG), critically reviewed the company's submission...
September 15, 2017: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"